Alterity Therapeutics Limited

Stage 4 · Declining · week 2

As of Oct 22, 2026, Alterity Therapeutics is in Stage 4, the downtrend phase, now in week 2 (since Oct 15, 2026). It closed at $2.15, 63.5% below its 52-week high and below its 200-day average, which is falling.

$2.15

-10.04% today

$39.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ATHE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 18w

S4 24w

S2 14w

S2 19w

S4 15w

S2 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 18w → S1 3w → S4 13w → S1 10w → S4 24w → S1 3w → S2 14w → S3 6w → S2 19w → S3 6w → S4 15w → S1 10w → S2 17w → S3 5w → S4 1w current

Total tracked: 165 weeks across 15 stage runs.

ATHE among Biotechnology371st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…371	ATHEAlterity Therapeutics Limited	Stage 4 · wk 2	21	−39.4%

vs 52W High

-63.5%

$2.15 lo$5.89 hi

63.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-46.5%

200 DMA: $4.02 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

2.30x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-39.4%

-52.6%

-50.8%

YTD

-32.0%

-54.8%

Scan Membership

Breakout Watch

Latest: 2025-05-23

5 appearances in last 60 days. First seen: 2019-04-30.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 2.30x

2026-10-21S4

Wk 1 · Vol 2.51x

2026-10-20S4

Wk 1 · Vol 0.81x

2026-10-19S4

Wk 1 · Vol 1.02x

2026-10-16S4

Wk 1 · Vol 2.74x

2026-10-15S43→4

Wk 1 · Vol 1.90x

2026-10-14S3

Wk 5 · Vol 2.84x

2026-10-13S3

Wk 5 · Vol 1.03x

2026-10-12S3

Wk 5 · Vol 1.76x

2026-10-09S3

Wk 5 · Vol 1.29x

2026-10-08S3

Wk 4 · Vol 2.03x

2026-10-07S3

Wk 4 · Vol 1.16x

Moving averages & range

50 DMA

$3.80

200 DMA

$4.02

52W High

$5.89

52W Low

$2.15

5D Low

$2.15

Resistance levels (recent highs)

20d High

$3.67

60d High

$4.91

120d High

$5.89

250d High

$5.89

Next resistance

+70.7%

to 20d High

ROE

-55.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.3

Alterity Therapeutics: quick answers

What stage is Alterity Therapeutics in?

As of Oct 22, 2026, Alterity Therapeutics (ATHE) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 15, 2026 and is in week 2. What the four stages mean

Is Alterity Therapeutics in an uptrend?

No. Alterity Therapeutics is in a Stage 4 downtrend. It trades 46.5% below its 200-day average, which is falling.

How far is Alterity Therapeutics from its 52-week high?

Alterity Therapeutics closed at $2.15 on Oct 22, 2026, 63.5% below its 52-week high of $5.89. Its 52-week low is $2.15.

How has Alterity Therapeutics performed over the past year?

As of Oct 22, 2026, Alterity Therapeutics is down 54.8% over the past year and down 32.0% so far in 2026.

Which sector and industry is Alterity Therapeutics in?

Alterity Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.